AUTOLOGOUS HEMATOPOIETC CELL TRANSPLANTATION (HCT) FOR HODGKIN LYMPHOMA, REAL WORLD EXPERIENCE OF A SINGLE CENTER EXPERIENCE
Objective: Hodgkin's Lymphoma (HL) during the years became a high curable hematology malignant disease. Despite high curable rates, up to 30% of patient will relapse or will be refractory to first line therapy (R/R). In this scenario, hematopoietic cell transplantation (HCT) is an important tre...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137923002389 |